Drug intelligence / Profile preview

TAP-1502

Development stage: Unknown
Lead developer: Shanghai Thederma
Modality: Small Molecules
Administration: Topical

Overview

TAP-1502 is a small molecule drug developed by Shanghai Thederma Pharmaceuticals for the treatment of immune system and skin diseases, specifically seborrheic dermatitis and psoriasis. It is being investigated as a topical spray formulation. The mechanism of action has not been publicly disclosed in available sources. As of June 2025, TAP-1502 is in Phase 2/3 clinical trials for seborrheic dermatitis in adults.

Beyond the preview

Go deeper on TAP-1502.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on TAP-1502.

Explore the full profile